CEO's open-market buy signals strong internal conviction. Monitor upcoming catalysts (pipeline updates, trial data, or partnership news) that could justify the purchase. No 10b5-1 plan indicated; this is a discretionary buy.
Price Chart
Executive Summary
Damora Therapeutics CEO Jarrett Jennifer made a single open-market purchase of 12,500 shares for $253K at $20.23/share on September 25, 2026. This is a conviction buy by the CEO, a strong standalone bullish signal per insider-trading literature, especially given the material dollar amount relative to typical insider purchases.
Key Financial Metrics
Key Facts
- CEO Jarrett Jennifer purchased 12,500 shares on the open market on September 25, 2026.
- Total purchase value: $253,000 at $20.23 per share.
- Single insider, no other insiders traded in the window; this is a standalone conviction buy, not a cluster.
Financial Impact
$253K open-market purchase by CEO; $253K is material for a typical small-cap biotech CEO buy.
Risk Factors
- Biotech insider buys can be pre-catalyst positioning; no specific catalyst mentioned in filing.
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| INSIDER-BUY Data (Synthetic) | 0001193125-26-403355 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 12, 2026 15d ago | Institutional Cluster | $20.26 | awaiting T+20 | — | $21.92 (+8.22%) |
Sep 28, 2026 29d ago | Insider Buy | $20.75 $21.26 | ▲ +2.46% | ▲ +2.49% | $21.92 (+5.64%) |
Aug 13, 2026 10w ago | EFFECT | $30.73 $28.10 | ▼ −8.56% | ▼ −6.81% | $21.92 (−28.67%) |
Aug 10, 2026 11w ago | Press Release | $30.36 $26.27 | ▲ +13.47% | ▲ +12.41% | $21.92 (+27.80%) |
Jul 20, 2026 14w ago | 8-K | $32.99 $31.80 | ▼ −3.61% | ▼ −6.17% | $21.92 (−33.56%) |
Apr 20, 2026 27w ago | 8-K | $26.82 $24.90 | ▼ −7.16% | ▼ −12.07% | $21.92 (−18.27%) |
Mar 23, 2026 31w ago | Press Release | $23.05 $26.82 | ▲ +16.36% | ▲ +8.94% | $21.92 (−4.90%) |
Mar 19, 2026 31w ago | Press Release | $18.14 $26.43 | ▲ +45.70% | ▲ +36.38% | $21.92 (+20.84%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers